Skip to ContentSkip to Navigation
About us Practical matters How to find us dr. M. (Hilde) Jalving


Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

Everolimus decreases [U-13C]glucose utilization by pyruvate carboxylase in breast cancer cells in vitro and in vivo.

Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement

Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers

Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol

Reinventing ESMO after the COVID-19 pandemic: moving towards a sustainable academic society

Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol

Abstract 5611: LAG-3 PET imaging in patients with cancer before immune checkpoint inhibitor therapy

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas

Read more


MEDtalks - Melanoomupdate 2024

Environmental impact to be included in package leaflets accompanying medication

European Oncologists Are Thinking Green

“Green” prescribing may limit the environmental impact of oncology

MEDtalks E-learning; Zeldzame melanomen en huidtumoren

Read more